Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02595359|
Recruitment Status : Completed
First Posted : November 3, 2015
Last Update Posted : April 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Endophthalmitis||Drug: Moxifloxacin||Phase 2|
Although cataract surgery is generally considered a safe procedure resulting in a favourable visual outcome, surgical complications do occur. The most feared complication is postoperative endophthalmitis which is an infectious condition caused by micro-organisms introduced to the interior of the eye during or after the surgical procedure.
As endophthalmitis is an infection, it should be preventable by antibiotic treatment.
Prophylactic antibiotic treatment can be given as topical treatment preoperatively, or during surgery directly into the anterior chamber, or as a subconjunctival, or it can be given as topical treatment postoperatively.
The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||June 20, 2018|
|Actual Study Completion Date :||June 20, 2018|
Experimental: moxifloxacin intracameral
moxifloxacin injection given at conclusion of cataract intervention
Other Name: Vigamox
- endothelial cell count [ Time Frame: 6-month; 1 year; 2 years ]
- endophthalmitis incidence [ Time Frame: 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02595359
|Recife, PE, Brazil, 50740600|
|Principal Investigator:||Rodrigo Lira||Prof|